Samsung Bioepis and Teva Enter into a Strategic Partnership for EPYSQLI® Commercialization in the U.S.
Samsung Bioepis and Teva Enter into a Strategic Partnership for EPYSQLI® Commercialization in the U.S.
01/10/25, 1:34 PM
Industry
pharmaceutical
biotechnology
health care
Type
partnership
Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. have entered into a strategic partnership for the commercialization of EPYSQLI® (eculizumab-aagh) in the United States. EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG).
Company Info
Additional Info
Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. are leading biopharmaceutical companies dedicated to enhancing the lives of patients with innovative access to treatments for healthcare systems, payers, providers, and patients.